Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tridacaine is a topical prescription product designed as an adhesive patch containing 5% lidocaine. It is indicated for the relief of pain associated with post-herpetic neuralgia and also used to reduce pain from minor skin conditions and moderate to severe chronic pain. Its active ingredient, lidocaine, is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion channels required for the initiation and conduction of nerve impulses, thereby blocking pain signal transmission at the site of application. The patch delivers lidocaine through the skin, providing local analgesic effects with minimal systemic absorption. The product is marketed in patch form to be applied directly to intact skin[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tridacaine.